Cary, North Carolina (PRWEB) March 17, 2015
Global Specimen Solutions, Inc. (http://www.globalspecimensolutions.com), an innovative specialty CRO focused on specimen management and informatics, announced today that Allen A Spizzo and Kay Gamble are joining the Board of Directors..
“Global Specimen Solutions, Inc. is excited to have two individuals with strong and diverse business expertise joining our Board of Directors to help guide our new growth phase for the company. Mr. Spizzo brings global business and financial expertise to our Board, and will help guide our financial development, planning and investment phases for informatics and growth. Ms. Gamble brings international marketing expertise across chemical and biotechnology sectors to our Board, helping launch our international approaches to Global Specimen Solutions marketing.” –Amelia Wall Warner, Founder and CEO.
Allen A. Spizzo has been a business and management consultant focused on the chemicals, materials, biotechnology and pharmaceutical industries, since November 2008, and he also serves as an investment adviser and asset management trustee. He served as Vice President and Chief Financial Officer of Hercules Incorporated (formerly NYSE:HPC) (“Hercules”), a former S&P 500 specialty chemicals company, from March 2004 until the company was sold to Ashland Inc. in November 2008. He served as Vice President, Corporate Affairs, Strategic Planning and Corporate Development of Hercules from July 2002 to March 2004. He served as Vice President, Investor Relations and Strategic Planning of Hercules from 2000 to July 2002. Prior to that, he served in other capacities with Hercules since 1979. Mr. Spizzo received a BS in Chemical Engineering from North Carolina State University and an MBA from University of Akron.
Mr. Spizzo is a chemical engineer with over 35 years of experience in the global chemicals and materials industry. By virtue of his Chief Financial Officer and other senior management positions with Hercules, he possesses the relevant financial leadership and management experience for a complex, global enterprise.
Kay Gamble is a marketing executive with Novozymes, a Danish-based biotechnology company. She has held sales, marketing and business development positions with Novozymes since 2000. She has outstanding experience from her career in working for technology leaders in the specialty chemicals and biotechnology sectors. She has developed expertise in bringing new ideas and new products to market, all the way from the concept phase through development, launch and implementation. The insights she has gained from working with a broad range of industries – Paint & Coatings, Personal Care, Food, Agriculture, Petroleum, Bioenergy and Automotive – will add a unique perspective and make her a valuable addition to the Board. Ms. Gamble earned a B.S. in Chemistry from the University of Delaware and a MBA from Drexel University.
Dr Warner will continue to chair the Global Specimen Solutions’ Board of Directors. “This is an exciting time for the company, and I am thrilled to have such accomplished business professionals guiding our company’s growth and planning. It is an honor to have Allen and Kay join our Board.” –Amelia Wall Warner, Founder and CEO.
Related Links: http://www.globalspecimensolutions.com
About Global Specimen Solutions, Inc.:
Founded in 2013, Global Specimen Solutions, Inc. is located in Cary, NC, where it provides pharmacogenomics and biorepository operational support for all phases of clinical studies and genomic biomarker programs. The Company works with academic and industry leaders to assure real-time collection, compliance, and usage of human specimens for research. Pharmacogenomic and biomarker research will result in development of safer, more effective medicines, enhance in-life drug development decisions, and improve patient medical treatment globally.